Core Team

  • Yang HuanfengChairman and CEO

    • Has nearly 30 years of experience in entrepreneurship and listed company operation and management; participated in the creation of Canature Health (300272), by serving as the president and hosting the listing application of the company.

      Has embarked on the third entrepreneurial journey together with Chairman Qu Jianguo and founded OriCell; possesses 2 industrial parks and 3 subsidiaries; has built 4 major business platforms.

      Work experience

      Once worked as an engineer at AVIC Shanghai Aero Measurement Controlling Research Institute (Computer Department); served successively as the deputy general manager and secretary of the board of directors at Shanghai Shenhua Holdings Co., Ltd. (600653 SHSY, one of the first eight companies listed on the Shanghai Stock Exchange, also known as the "Old Eight Companies"). From 2001 to 2017, served as chairman of Shanghai Canature Health Technology Group Co., Ltd. (Canature Health 300272) and was devoted to the development of residential water treatment products during her tenure. From 2015 to 2020, served as the president of OriCell Technology Group. During this period, OriCell invested 1.5 billion yuan to build OriCell Group in Shanghai Zhangjiang Hi-Tech Park. The company owns the world's largest fully automated immune cell bank. By cooperating with China's scientific research institutions in R&D of immune cell-based tumor prevention and treatment technologies and integrating resources from many sectors, the company strives to build a big health industry chain for anti-aging, elderly care, and healthcare. From 2015 to the present, Ms. Yang has been serving as the chairman and general manager of OriCell Therapeutics (Shanghai) Co., Ltd. Under her leadership, the team has completed the construction of 4 patented technology platforms, independently developed a series of advanced innovative product lines, and applied for more than 50 patents.Canature Health is the first listed company in China's residential water treatment industry.

  • Dr. He XiaowenCo-founder & CSO

    • The co-founder & CSO, who is fully responsible for the construction and development of the company's scientific system and innovative technology platform.

      Education Background

      Having a doctoral degree in molecular biology and genetics from the Second Military Medical University; a postdoctoral fellow at the University of Medicine and Dentistry NJ.

      Work experience

      Has more than 20 years of experience in scientific research and achievement transformation in the fields of biological immunity, vaccines, immune cell therapy, and stem cells. Developed the therapeutic Serratia marcescens (LEISHUYING), which won the National Class I New Drug Certificate for New Biological Products, and hosted a liver cancer vaccine research, which won the second prize of the Army Science and Technology Progress Award. Participated in the R&D of a tumor NKT cell therapy, which received special funding from the Twelfth Five Year National Major New Drug Project. This tumor NKT cell therapy has been applied in the treatment of more than 200 cases of malignancies in the First Affiliated Hospital of Tsinghua University. Has published more than 30 SCI papers and obtained 22 invention patents.

      Currently serves as the deputy director of Shanghai Cell Therapy Clinical Translational Engineering Technology Research Center, deputy director of the First Special Committee of Targeting and Cell Therapy of Pudong New Area Medical Association, and visiting professor at Shanghai Zhongshan Hospital, University of Shanghai for Science and Technology, Shanghai Health Medical College, and Shanghai University of Traditional Chinese Medicine.

      e company's unparalleled superiority in the innovation of product lines and accelerated the progress of clinical development and international strategic cooperation.

  • Weidong CuiChief Technology Officer

    • As CTO, responsible for the development of new technology, production, management of operations and accelerating the clinical trial process of solid tumor targeting products and future business developments.


      Dr. Weidong Cui have over 20 years of experience in the field of developing Bologics and Cell Therapy drugs, complete process management of GMP and commerical operations, and focuses on the development, production, registration and commerical operation of cutting edge immunotherapy products. Before joining OriCell Therapeutics, Dr. Cui held the position of Cheif Technology Officer of FOSUNKite, lead a team efficiently through the process of GMP production, IND registration, clinical trials and NDA registration of the first CAR-T product in China, which became the first commerical CAR-T product with NMPA certification in China.